Novartis AG (XTER:NOT) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NOT Novartis AG XTER:NOT
78 GF Score
Price €134.60
GF Value €113.29
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XTER:NOT
78GF Score
Novartis AG XTER:NOT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis AG (XTER:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.60 is trading 18.8% above its estimated GF Value™ of €113.29. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for XTER:NOT:

  • Dividends Received:
  • GF Value™: €113.29 vs. price of €134.60 (18.8% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XTER:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
78GF Score

Get the complete analysis for XTER:NOT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.60
Price
€113.29
GF Value